EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.341
https://www.valueinhealthjournal.com/article/S1098-3015(23)03471-X/fulltext
Section Title :
Section Order :
12365
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03471-X&doi=10.1016/j.jval.2023.09.341